Abstract: Disclosed herein is pyrroline-carboxy-lysine (PCL), a pyrrolysine analogue, which is a natural, biosynthetically generated amino acid, and methods for biosynthetically generating PCL. Also disclosed herein are proteins, polypeptides and peptides that have PCL incorporated therein and methods for incorporating PCL into such proteins, polypeptides and peptides. Also disclosed herein is the site-specific derivatization of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein. Also disclosed herein is the crosslinking of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein.
Type:
Application
Filed:
May 15, 2014
Publication date:
October 9, 2014
Applicant:
IRM LLC
Inventors:
Bernhard GEIERSTANGER, Weijia OU, Susan E. CELLITTI, Tetsuo UNO, Tiffany CROSSGROVE, Hsien-Po CHIU, Jan GRUNEWALD, Xueshi HAO
Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
Type:
Application
Filed:
March 12, 2014
Publication date:
September 18, 2014
Applicants:
IRM LLC, NOVARTIS AG
Inventors:
Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
Abstract: The present invention provides compounds of Formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.
Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.
Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.
Type:
Application
Filed:
March 13, 2014
Publication date:
September 18, 2014
Applicants:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION, IRM LLC
Inventors:
Arnab Kumar CHATTERJEE, Fang LIANG, Casey Jacob Nelson MATHISON, Pranab Kumar MISHRA, Valentina MOLTENI, Advait Suresh Nagle, Frantisek SUPEK, Liying Jocelyn TAN, Agnes VIDAL, Michael Herman GELB, Frederick Simmons BUCKNER, Hari Babu TATIPAKA, Neil Richard NORCROSS, John Robert GILLESPIE
Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFR?, PDGFR?) kinases.
Type:
Application
Filed:
April 22, 2014
Publication date:
August 14, 2014
Applicant:
IRM LLC
Inventors:
Valentina MOLTENI, Hank Michael James PETRASSI, Xiaolin LI, Xiaodong LIU, Jon LOREN, Juliet NABAKKA, Bao NGUYEN, Vince YEH
Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of PDGFR (PDGFR?, PDGFR?) kinases or c-kit and PDGFR (PDGFR?, PDGFR?) kinases.
Type:
Application
Filed:
August 31, 2012
Publication date:
July 24, 2014
Applicants:
NOVARTIS PHARMACEUTICALS UK LIMITED, IRM LLC
Inventors:
Fang Liang, Michael Gibney, Vince Yeh, Xiaolin Li, Valentina Molteni, Duncan Shaw, Ashley Mitchell Berman, Sarah Lewis, Jon Loren, Vikki Furminger
Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.
Type:
Application
Filed:
November 18, 2013
Publication date:
June 5, 2014
Applicants:
Novartis AG, IRM LLC
Inventors:
Arnab Kumar Chatterjee, Advait Suresh Nagle, Prasuna Paraselli, Ravinder Reddy Kondreddi, Seh Yong Leong, Pranab Kumar Mishra, Robert Joseph Moreau, Jason Thomas Roland, Wei Lin Sandra Sim, Oliver Simon, Liying Jocelyn Tan, Bryan KS Yeung, Bin Zou, Venkatataiah Bollu
Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).
Type:
Grant
Filed:
March 30, 2007
Date of Patent:
May 13, 2014
Assignee:
IRM LLC
Inventors:
Xiaohui He, Kunyong Yang, Hong Liu, David Archer Ellis
Abstract: The present invention provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a (“PCSK9”) and methods of using such antibodies.
Type:
Grant
Filed:
December 10, 2010
Date of Patent:
April 29, 2014
Assignees:
IRM LLC, Novartis AG
Inventors:
Sarah Rue, Steve B. Cohen, Jun Li, David Yowe
Abstract: The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.
Type:
Application
Filed:
April 5, 2013
Publication date:
April 24, 2014
Applicants:
THE SCRIPPS RESEARCH INSTITUTE, IRM LLC
Inventors:
ANTHONY E. BOITANO, MICHAEL COOKE, SHIFENG PAN, PETER G. SCHULTZ, JOHN TELLEW, YONGQIN WAN, XING WANG
Abstract: The invention provides methods for using compounds of Formula (I) for treating an EML4-ALK+ mediated condition such as EML4-ALK+ non-small cell lung cancer, and optionally resistant to crizotinib; wherein R1, R2, R3, R4, R5 and R6 are as defined above.
Type:
Grant
Filed:
February 2, 2012
Date of Patent:
April 22, 2014
Assignee:
IRM LLC
Inventors:
Nanxin Li, Jennifer Leslie Harris, Peter McNamara, Fangxian Sun
Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
Type:
Application
Filed:
February 17, 2012
Publication date:
February 6, 2014
Applicants:
IRM LLC, The Scripps Research Institute
Inventors:
Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
Abstract: The present invention provides improved antibodies or antigen-binding molecules that specifically recognize and agonize the tyrosine receptor kinase B (TrkB) receptor, and methods of their use. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.
Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFR?, PDGFR?) kinases.
Type:
Application
Filed:
September 19, 2013
Publication date:
January 30, 2014
Applicant:
IRM LLC
Inventors:
Valentina MOLENTI, Hank Michael James Petrassi, Xiaolin Li, Xiaodong Liu, Jon Loren, Juliet Nabakka, Bao Nguyen, Vince Yeh
Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.
Type:
Grant
Filed:
September 8, 2011
Date of Patent:
January 28, 2014
Assignee:
IRM LLC
Inventors:
Yi Fan, Jon Loren, Valentina Molteni, Pamela A. Albaugh, Gregory Chopiuk, Jeffrey M. Smith, Brenton T. Flatt
Abstract: The present invention provides compounds of Formula I or II: wherein R1, R1b, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds of Formula (I) or (II) and pharmaceutical compositions thereof are useful for the treatment of B-Raf-associated diseases.
Type:
Application
Filed:
September 10, 2013
Publication date:
January 9, 2014
Applicants:
NOVARTIS AG, IRM LLC
Inventors:
Abran Q. Costales, Shenlin Huang, Jeff Xianming Jin, Zuosheng Liu, Sabina Pecchi, Daniel Poon, John Tellew
Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).
Type:
Application
Filed:
August 29, 2013
Publication date:
December 26, 2013
Applicant:
IRM LLC
Inventors:
Valentina MOLTENI, Xiaolin Li, Juliet Nabakka, David Archer Ellis, Beth Anaclerio, Enrique Saez, John Wityak
Abstract: The present invention provides a compound the invention, and its use as a IGF-1R inhibitor. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Type:
Application
Filed:
March 8, 2012
Publication date:
December 19, 2013
Applicants:
IRM LLC, NOVARTIS AG
Inventors:
Bei Chen, Robin Alec Fairhurst, Songchun Jiang, Wenshuo Lu, Thomas H. Marsilje, III, Clive McCarthy, Pierre-Yves Michellys, Stefan Stutz
Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.
Type:
Application
Filed:
February 23, 2012
Publication date:
December 12, 2013
Applicant:
IRM LLC
Inventors:
Valentina Molteni, Yi Fan, Jon Loren, Jeffrey M. Smith, Brenton T. Flatt